HIV-associated facial lipoatrophy
Infectious disease · 2008–2009
3decisions
1medicine
0carried consumer input
0individual submissions
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| poly-l-lactic acid treatment of facial lipoatrophy caused by therapy for HIV infection | Mar 2009 | Recommended with restriction | unclear |
| poly-L-lactic acid Treatment of severe facial lipoatrophy caused by antiretroviral therapy in HIV-positive patients. | Mar 2009 | Recommended with restriction | unclear |
| poly-L-lactic acid Treatment of facial lipoatrophy caused by antiretroviral therapy in HIV positive patients. | Nov 2008 | Recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.